44 citations
,
May 2023 in “MedComm” PROTAC technology shows promise for cancer treatment but needs more effective E3 ligase recruiters.
June 2024 in “Journal of Clinical Oncology” Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
10 citations
,
September 2016 in “Journal of cutaneous medicine and surgery” Patients on dabrafenib and trametinib for melanoma often experience skin side effects.
July 2023 in “Dermatology practical & conceptual” Low dose oral minoxidil helped treat long-term hair loss caused by chemotherapy in 15 patients.
Sintilimab with chemotherapy improves survival and response in advanced lung cancer but increases some side effects.
December 2015 in “OPAL (Open@LaTrobe) (La Trobe University)” QLT0267 stops hair follicle cell growth and movement.
January 1987 in “Chronica Dermatologica” 2 citations
,
May 2008 in “Journal of Clinical Oncology” AZD6244 treatment causes skin aging effects by depleting skin stem cells.
20 citations
,
February 2015 in “Anais brasileiros de dermatologia/Anais Brasileiros de Dermatologia” A 6-year-old girl was diagnosed with a rare hair disorder and started treatment with topical minoxidil.
14 citations
,
August 2017 in “International Journal of Immunopathology and Pharmacology” Photodynamic therapy improved skin issues from sorafenib when other treatments failed.
1 citations
,
May 2025 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are effective for alopecia areata, but more research is needed to determine which is better.
37 citations
,
May 2016 in “JAAD case reports” Oral minoxidil shows promise in treating monilethrix-related hair loss.
2 citations
,
November 2024 in “JAAD Case Reports” March 2026 in “The Journal of Dermatology” Ritlecitinib is cost-effective for severe alopecia areata in Japan.
32 citations
,
September 2015 in “Dermatology” Certain leukemia drugs can cause severe skin reactions that may require stopping treatment.
8 citations
,
May 2019 in “Journal of dermatological treatment” Vismodegib is effective for basal cell carcinoma but has severe side effects.
April 2020 in “The FASEB journal” Poncirin is a promising inhibitor of Janus Kinase 3, potentially better than tofacitinib.
1 citations
,
April 2023 in “Heliyon” Disitamab vedotin and gemcitabine effectively treated bladder cancer without major side effects.
2 citations
,
December 2023 in “Journal of clinical immunology” Ruxolitinib significantly improves multiple autoimmune conditions in APS-1 patients.
4 citations
,
March 2007 in “British Journal of Dermatology” Gefitinib therapy can cause unusual hair growth on the nose.
6 citations
,
December 2021 in “Journal of Cancer Research and Therapeutics” The treatment improved survival and controlled cancer spread but required managing side effects like rashes.
2 citations
,
October 2018 in “Archives of Dermatological Research” Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.
14 citations
,
January 2017 in “Pharmacological Reports” TP0427736 may help treat hair loss by blocking a specific protein and promoting hair growth.
33 citations
,
January 2018 in “Blood” Ruxolitinib helps protect skin stem cells and keeps skin healthy in mice with skin GVHD.
54 citations
,
September 2012 in “Acta ophthalmologica” Cancer treatments can cause various eye problems, so eye doctors should know how to diagnose and treat these early.
8 citations
,
August 2018 in “BMJ Case Reports” Pazopanib treatment caused rapid hair color loss, possibly indicating its effectiveness.
43 citations
,
March 2017 in “Drug Design Development and Therapy” The new nanoparticles could improve melanoma treatment by working better than current options.
September 2023 in “SKIN The Journal of Cutaneous Medicine” Talquetamab may cause hair loss and skin issues.
August 2018 in “SDÜ SAĞLIK BİLİMLERİ DERGİSİ” No method fully prevents hair loss from chemotherapy, but some methods can reduce it and improve quality of life.
39 citations
,
March 2009 in “Dermatology Online Journal” Erlotinib can cause persistent excessive hair growth.